The world’s largest buyer of biopharmaceutical royalties has set up its first Asia-Pacific base in Hong Kong, joining a string of multinational corporations in the pharmaceutical sector establishing offices in the city as out-licensing deals by mainland Chinese biotechnology firms hit record highs.
Royalty financing gives drug developers an alternative way to raise capital even as US investment restrictions loom, according to an expert.
“Chinese biotech firms would need royalty financing as an…